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Background: Patients suffering from malignancies often undergo serial positron emission tomography - computed
tomography (PET-CT) scans, using 2-deoxy-2-[18F] fluoro-D-glucose (FDG) for diagnosis and follow up. This principle
may also be applied to benign conditions as inflammatory cells take up increased amounts of FDG as well. The aim
of our study was to retrospectively review the cytological diagnoses made at EUS-FNA of FDG-avid PET-CT lesions
in patients with a history of cancer and to determine whether the cause of FDG-avidity was neoplastic or benign.
Methods: We used the endoscopy database to extract clinical information on all patients with malignancies who
underwent EUS-FNA to obtain tissue from FDG-avid nodes seen on PET-CT at our institution from 2009 – 2012. All
patients who were referred for EUS-FNA after their scans were included. Those who had contraindications to endoscopic
procedures were excluded.
Results: The most common location of positive lymph nodes was the subcarinal region (46%). A definitive diagnosis
was obtained in 87.8% cases, of which 51.2% had a diagnosis of malignancy confirmed on cytology, while 36.5% were
benign. Out of these, 29% had granulomatous inflammation. In 12.2% of cases no definitive diagnosis was obtained.
Conclusion: Our results show that great caution should be exercised when evaluating FDG-avid PET-CT nodes in patients
with known malignant disease, as a significant proportion of these lesions may be benign, particularly in geographic
locations with a high background prevalence of granulomatous inflammation.
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Patients suffering from malignant neoplasms will often
undergo serial positron emission tomography - computed
tomography (PET-CT) scans, using 2-deoxy-2-[18F]
fluoro-D-glucose (FDG), for initial diagnosis, follow up
during treatment, and to detect relapse [1]. The increased
uptake of FDG in neoplastic lesions, due to their high
glycolytic activity, makes PET-CT an extremely useful tool
in the diagnosis and follow-up of malignancy [1]. How-
ever, this same principle may also be applied to the* Correspondence: aasim@skm.org.pk
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unless otherwise stated.diagnosis and monitoring of benign conditions [1-5]. It
is postulated that inflammatory cells and mediators
take up increased amounts of FDG, leading to high
standard uptake values (SUV) in the setting of infec-
tion and inflammation [1,3,4]. This can often lead to
false positive results in malignancy, where inflamma-
tion or infection may be mistaken for active malignant
disease [4]. In countries with a high prevalence of
granulomatous inflammation, such as tuberculosis, dis-
tinguishing between the two becomes even more im-
portant. Such areas include large parts of Asia and
Africa, which have a very high prevalence of tubercu-
losis [6]. 22 countries are responsible for 80% of thetd. This is an Open Access article distributed under the terms of the Creative
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fourteenth [7]. Endoscopic ultrasound guided fine nee-
dle aspiration (EUS-FNA) provides a useful and low
risk means of obtaining cytological samples from le-
sions seen at PET-CT and distinguishing between ma-
lignancy and other causes of FDG-avidity, such as
infection or inflammation [5,8].
The aim of our study was to retrospectively review the
cytological diagnoses made at EUS-FNA of FDG-avid
PET-CT lesions in patients with a known history of ma-
lignant neoplasms and to determine whether the cause
of FDG-avidity was a neoplastic or a benign/inflamma-
tory process.
Methods
We used the endoscopy database to extract information
on all patients with malignant neoplasms who under-
went EUS-FNA of FDG-avid nodes seen on PET-CT
scan at our institution from 2009 – 2012. We included
all patients who were referred for EUS-FNA after their
PET-CT scans. The patients who were excluded were
those who had contraindications to endoscopic proce-
dures, including but not limited to, coagulopathy, gastro-
intestinal tract obstruction preventing access to the area
of interest and inability to open the mouth, preventing in-
sertion of the echo-endoscope. Clinical information, im-
aging findings, EUS findings and cytopathology results
including the results of rapid on-site evaluation (ROSE)
were collected. Lymph nodes seen on PET-CT were con-
sidered to be FDG-avid if the standard uptake value
(SUV) was > 2.5.
After approval from the institutional review board, a
total of forty-one patients were selected for this study.
All PET-CT scans were done on a Philips Gemini TF 16
slice multi-detector computed tomography scanner. The
dose of FDG F18 to be administered was determined ac-
cording to the weight of the patient, and ranged from
300-450 MBq for a weight range of 60 kg to 100 kg.
Scans were performed approximately 50 minutes after
administration of FDG. Whole-body CT scan was per-
formed initially, starting from the skull vertex to the
mid-thighs with contiguous slices of 5 mm thickness.
Depending upon the clinical indication, intravenous con-
trast was also administered. After CT, PET data was ac-
quired with the patient lying absolutely still in the same
position. The data was acquired starting from the thighs
and proceeding towards the head, that is, in a direction
opposite to that for CT image acquisition. Typically, 6-8
bed positions were taken with 2-5 minutes acquisition at
each position, depending on the patient’s body mass
index (BMI). All data obtained is corrected for dead
time, scatter, random counts and attenuation, automatic-
ally. The threshold value of metabolic index was set at 2.5
because this is the approximate physiologic backgrounduptake of FDG in the body (range: 0.5 to 2.5), and is usu-
ally calculated using the liver as a reference point [9]. The
standard uptake value, or SUV, is a semi-quantitative as-
sessment of the radiotracer from a static PET image. It is
calculated using the formula below:
tracer activity in tissue= injected dose= patient weightð Þ:
We measured the maximum SUV in any region of
interest. If hypoglycemic agents were used, in diabetic
patients, then a glucose-corrected SUV was used, calcu-
lated using standard formulae.
Written informed consent for EUS-FNA was obtained
from all adult patients or from legal guardians of those
below the age of eighteen. All procedures were carried out
under conscious sedation, using midazolam and pentazo-
cine, except in four paediatric patients, aged 4 – 14 years,
in whom the procedure was performed under general
anesthesia. EUS was carried out using an Olympus linear
array echo-endoscope, and EUS-FNA was performed
using a disposable 22-gauge FNA needle in each case. All
procedures were carried out by a single, experienced
gastroenterologist. Aspirates were smeared and air-dried,
or fixed in 95% alcohol. Using the Diff-Quik stain for
ROSE, air dried slides were prepared by a trained cyto-
technologist within the endoscopy room and were evalu-
ated immediately by a cytopathologist. Alcohol-fixed
slides were later stained using the Papanicolaou stain;
samples were also saved for cell-block preparation. ROSE
ensured sample adequacy, provided a preliminary diag-
nosis and helped to decide on the need for immuno-
histochemical stains. In patients known to have a
lymphoproliferative disorder, part of the aspirate was
saved in RPMI (Roswell Park Memorial Institute Medium)
for subsequent flow cytometry studies.
The institutional review board that approved the study
is the Shaukat Khanum Memorial Cancer Hospital &
Research Centre Institutional Review Board.
Results
Of the 41 patients studied (age range: 4–78 years; mean
age 37.8 years), 14 (34%) were female and 27 (66%) were
male. The majority of the patients (n = 24, 58.5%) had an
existing diagnosis of classic Hodgkin's lymphoma, followed
by diffuse large B-cell lymphoma in 5 (12.2%) (Table 1).
Overall, 76% of patients included had lymphoma, while the
remainder had a variety of other neoplasms, as one would
expect in a tertiary care cancer facility. Of the FDG avid
nodes sampled, 19 (46%) were located in the subcarinal re-
gion (Figure 1).
An average of 2.2 passes were made in order to obtain
adequate material for analysis (range: 1–5 passes). A de-
finitive diagnosis was obtained in 36/41 (87.8%) cases, of
which 21/41 (51.2%) had a diagnosis of malignancy
Table 1 Types of cancers diagnosed
Type Frequency; (%age)
percentage
Classic Hodgkin’s Lymphoma 24; (58 · 5)
Diffuse Large B-cell Lymphoma 5; (12 · 2)
Ovarian Carcinoma 4; (9 · 7)
Gastrointestinal Stromal Tumour 2; (4 · 9)
Esophageal Carcinoma 1; (2 · 4)
Malignant Melanoma 1; (2 · 4)
Non-Hodgkin’s Lymphoma 1; (2 · 4)
T-cell Lymphoma 1; (2 · 4)
Rectal Adenocarcinoma 1; (2 · 4)
Hepatocellular Carcinoma 1; (2 · 4)
Total: 41; (100)
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Out of these, 12 (29%) had granulomatous inflammation
(Table 2). Only one patient out of twelve with granu-
lomatous inflammation was smear-positive for Ziehl-
Neelsen stain for acid-fast bacilli. Samples from 9 of
these 12 patients were also sent for acid-fast bacilli cul-
tures, all of which were negative.
In 5 patients, the results of EUS-FNA were inconclu-
sive, a figure which included two patients in whom the
FNA material showed necrosis only.
Cytopathology results were also reviewed. Three patients
with lymph nodes showing metastatic ovarian carcinoma
(diagnosed as metastatic adenocarcinoma) showed groups
and sheets of atypical cells having high nucleus to cyto-
plasm ratio, overlapping and pleomorphic vesicular to
hyperchromatic nuclei with inconspicuous to rarely con-
spicuous nucleoli, ill defined cytoplasmic borders and cyto-
plasmic vacuolations. Metastatic rectal adenocarcinoma
had groups of atypical columnar cells forming acini/glands
with pleomorphic nuclei and necrosis in the background.











Figure 1 Distribution of FDG avid nodes sampled.scattered loose aggregates of epithelioid histiocytes, few
giant cells and rarely necrosis with mixed inflammatory
cells in the background. Reactive lymph nodes showed a
heterogeneous population of lymphoid cells in different
stages of maturation and anthracotic, pigment-laden mac-
rophages in a few cases. No atypical lymphoid cells were
seen in these smears. In nodes considered positive for clas-
sic Hodgkin’s lymphoma, a heterogeneous population of
lymphoid cells, macrophages and rare eosinophils were
seen with atypical mononuclear and bi-nucleated lymphoid
cells showing large prominent nucleoli. Lymph nodes with
FNA diagnoses of diffuse large B-cell lymphoma showed
population of large cells with conspicuous nucleoli, high
nuclear-cytoplasmic ratio and increased mitotic activity.
FNA of GIST showed spindled cells showing mild to mod-
erate nuclear atypia and inconspicuous nucleoli.
Immunohistochemical stains were used on 17 (41%)
samples. 11 (64%) samples showed CD30 positive atyp-
ical mono- and bi-nucleated cells confirming the diagno-
sis of classic Hodgkin’s lymphoma. One sample was
positive for both CD3 and CD45 (leukocyte common anti-
gen) and negative for CD20, confirming T-cell lymphoma.
CDX2 positivity (rectal adenocarcinoma) and CD117 posi-
tivity (GIST) was seen in one sample each. We found two
samples to be negative for CD15, these were confirmed
as classic Hodgkin’s lymphoma on the basis of CD30
positivity.
Nine patients had FDG-avid lymph nodes biopsied to
check for residual disease. Of these, 3/9, or 33.3%, were
due to benign processes. Granulomatous inflammation
was seen in all three of these patients. Of the other six
cases, four had residual cancer, while EUS-FNA sam-
pling was inconclusive in two patients, one of which had
necrosis on aspirate.
28 patients were found to have FDG-avid lesions dur-
ing imaging for regular follow-up of neoplasia. 17/28
were found to have relapse of cancer, 9/28 (32%) had be-
nign disease, with granulomatous inflammation in eight
Table 2 Definitive diagnoses obtained at EUS-FNA
Diagnosis Frequency; (%age)
Malignant:
Classic Hodgkin’s Lymphoma 13; (31 · 7)
Diffuse Large B-cell Lymphoma 1; (2 · 4)
T-cell Lymphoma 1; (2 · 4)
Ovarian Carcinoma 3; (7 · 3)
Rectal Adenocarcinoma 1; (2 · 4)
Gastrointestinal Stromal Tumour 2; (4 · 8)
Total malignant 21; (51 · 2)
Benign:
Granulomatous Inflammation 12; (29 · 2)
Reactive lymph node 3; (7 · 3)
Total Benign 15; (36.5)
Total (Definitive Diagnosis) 36; (87.8)
Inconclusive 5; (12.1)
Total (Overall) 41; (100)
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cytology results were inconclusive.
3/4 patients who underwent EUS-FNA of FDG avid le-
sions as part of their initial staging process had benign
cytological diagnoses – reactive lymph nodes in two pa-
tients, and granulomatous inflammation in one patient.
Inconclusive results, as demonstrated by necrotic changes,
were seen in the fourth patient.
Four patients had previously received radiotherapy to
the area from which EUS-FNA was to be performed.
Three of these four patients had received radiotherapy
to the chest and now presented with FDG-avid subcar-
inal nodes in two patients and an FDG-avid aorto-
pulmonary window node in one patient. The fourth of
these patients had received upper abdominal radiother-
apy and now presented with FDG-avid coeliac nodes. All
four of these patients had relapsed malignant disease on
biopsy of the nodes of interest. Lymphoma was diagnosed
in 3 patients whereas 1 patient had adenocarcinoma.
3 patients had a prior history of tuberculosis and 2 of
these had granulomatous disease on biopsy of FDG avid
nodes while 1 had reactive inflammatory findings.
Discussion
Patients suffering from malignant disease are usually re-
quired to undergo imaging investigations not only for
diagnosis but also regularly during treatment and as part
of regular follow up. This latter process often involves
many years of careful surveillance following treatment
for recurrent disease [5]. Additionally, symptoms sug-
gesting recurrence may warrant further imaging and
other studies. The assessment of lymph nodes using CT
currently relies on the size and appearance of the node,rather than on its functional characteristics. On CT, a
normal lymph node is typically <1 cm in size, with
smooth and well-defined borders, a central fatty hilum
and a homogeneous density. Typically, nodes which are
larger than 1 cm in diameter, with a rounded appearance
and heterogeneous density are considered to be malig-
nant, especially when multiple such nodes are seen. CT
therefore relies on somewhat insensitive size and mor-
phologic criteria and is less accurate than PET-CT in
characterizing lymph nodes. This is because not all en-
larged nodes are malignant, and small or non-enlarged
nodes may still harbour malignancy [10].
However, inflammation can mimic malignancy on
PET-CT and it is not possible, at present, to distinguish
between these using imaging criteria alone [11]. This
sometimes leads to patients being mislabeled as having
metastatic or recurrent disease [5]. For this purpose, it is
imperative that FDG-avid lesions seen on PET-CT scans
are interpreted correctly.
In our review we found that 36.5% of patients with
FDG-avid lymph nodes on PET-CT, all of whom had ei-
ther active neoplasia or a past history of malignancy, actu-
ally had benign lesions when these nodes were subjected
to EUS-FNA. The most common benign disease seen in
this situation was granulomatous inflammation. Quite ob-
viously, this has major implications on patient staging,
treatment and prognosis. All patients included in the
study had a pre-existing diagnosis of malignancy. The in-
dication for the PET-CT was, in the main, for follow up
after treatment, to assess disease response or to check for
residual disease.
Our results are comparable to those of Fritscher-
Ravens et al. who reported 21 (41.17%) benign lesions
out of a total of 51 adequate samples from patients with
cancer who were suspected of recurrence [5]. However,
Fritscher-Ravens et al. only focused on mediastinal le-
sions whereas we sampled lesions from multiple loca-
tions [5]. To our knowledge, ours is the first study that
has included FDG-avid PET-CT lesions from multiple
sites.
Another study on lung cancer, by Eloubeidi et al.,
found the rate of benign lesions to be as high as 64%
[12]. Their higher rate of positivity, however, is likely to
be because they included patients with suspected lung
cancer in their study, whereas in our study all patients had
a confirmed background diagnosis of cancer. Fritscher-
Ravens et al. found the majority of benign results to be due
to inflammatory changes, with granulomatous inflamma-
tion following close behind [5]. In comparison, we found a
much higher percentage of granulomatous inflammation
in our patients, (12/15 benign lesions). This is likely to re-
flect the high background prevalence of tuberculosis in this
part of the world. However, despite the high rate of granu-
lomatous inflammation in our cohort, only one sample was
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the known low sensitivity of this stain. We do not routinely
use other stains, such as auramine-rhodamine or immuno-
fluorescence for AFB to detect AFB at our institution. 9
out of 12 patients with granulomatous inflammation had
cultures for AFB done, all of which were negative. In con-
trast with the work of Fritscher-Ravens et al. we found a
much lower proportion of patients with reactive lymph
nodes (3/15) [5].
We classified necrotic changes on cytopathology as in-
conclusive results because excisional biopsies were not
done and it cannot be said with certainty if the necrosis
was limited to only the area that was sampled or affected
the entire node.
False-positive FDG-avid PET-CT lesions have mainly
been reported in cases of granulomatous processes such
as tuberculosis and sarcoidosis [4,13]. This makes our
results relevant not only for regions where tuberculosis
is widespread, such as South Asia and Africa, but also
for other parts of the world with large immigrant popu-
lations derived from these areas. Therefore, extreme
caution should be exercised when interpreting positive
PET-CT results in these patients. A similar conclusion
was reached by Goo et al. [2]. We feel that oncologists
and others treating cancer patients who regularly obtain
PET-CT studies on their patients as part of this process
need to be aware of these findings. While EUS-FNA was
only performed on FDG-avid nodes, one cannot com-
pletely rule out the possibility of a node which is nega-
tive on PET-CT (i.e. non - FDG-avid) still harbouring a
focus of malignancy.
We found that 3/9 patients who were sampled during
treatment had benign conditions on cytology, all of
which were granulomatous inflammation. For patients
who underwent EUS-FNA during their follow-up period,
9/28 (32.1%) had benign lesions, of which eight were
granulomatous inflammation. These are significant false
positive rates for lesions that mimic cancer, in the setting
of cancer, but are in fact benign lesions. Without EUS-
FNA, these patients might well have been assumed to
have residual cancer, and been subjected to further, po-
tentially hazardous, treatment.
Schaefer et al. and Crocchiolo et al. discussed in their
reports that 10-40% of FDG avid nodes on PET-CT,
thought to be malignant, actually turn out to be benign
[14,15]. In keeping with this, we found that 32.4%
(12/37) of patients with known malignancy, now post-
treatment, had benign results on biopsy of FDG-avid
nodes seen on PET-CT. Our review may have been
limited by the small sample size. Also, since two dif-
ferent cytopathologists evaluated our specimens, there
may have been subjective variation in the interpret-
ation of the findings. We were not limited by inad-
equate sampling, however, since we achieved a highrate of definitive diagnosis (92.6%), with an average of
2.2 passes.
Our review demonstrates that extreme caution should
be exercised when evaluating FDG-avid lymph nodes on
PET-CT in patients with known malignant disease, as a
significant proportion of FDG-avid lesions may be be-
nign. In our series, 36.5% had non-malignant conditions,
with granulomaotus inflammation being the most com-
mon non-malignant lesion seen. Our results are of par-
ticular significance to physicians practicing in settings
where granulomatous inflammatory diseases are wide-
spread and also of importance for oncologists, and other
physicians, practicing elsewhere in the world, who regu-
larly deal with patients from these areas. These results
have the potential to significantly impact patient diagno-
sis, staging and subsequent management. Many patients
will be able to discontinue cancer treatment sooner, or
to avoid unnecessary re-treatment, as a result of an ap-
propriate diagnostic intervention such as EUS-FNA,
when FDG-avid nodes are seen on PET-CT scan. This
has significant impact in improving quality of life in
these patients and all physicians treating such patients
need to be aware of these important findings.
Conclusion
Our results show that great caution should be exercised
when evaluating FDG-avid lymph nodes on PET-CT in
patients with known malignant disease, as a significant
proportion of these lesions may be benign. Failure to es-
tablish a tissue diagnosis in such a situation can lead to
patients being treated inappropriately, with potential for
harm to the patient. We recommend that all such le-
sions need to be sampled and an accurate diagnosis
made prior to instituting, or making changes to, therapy.
EUS-FNA, with rapid on-site evaluation offers an opti-
mal means of sampling such lesions.
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